These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships. Vanotti E; Amici R; Bargiotti A; Berthelsen J; Bosotti R; Ciavolella A; Cirla A; Cristiani C; D'Alessio R; Forte B; Isacchi A; Martina K; Menichincheri M; Molinari A; Montagnoli A; Orsini P; Pillan A; Roletto F; Scolaro A; Tibolla M; Valsasina B; Varasi M; Volpi D; Santocanale C J Med Chem; 2008 Feb; 51(3):487-501. PubMed ID: 18201066 [TBL] [Abstract][Full Text] [Related]
6. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Montagnoli A; Valsasina B; Croci V; Menichincheri M; Rainoldi S; Marchesi V; Tibolla M; Tenca P; Brotherton D; Albanese C; Patton V; Alzani R; Ciavolella A; Sola F; Molinari A; Volpi D; Avanzi N; Fiorentini F; Cattoni M; Healy S; Ballinari D; Pesenti E; Isacchi A; Moll J; Bensimon A; Vanotti E; Santocanale C Nat Chem Biol; 2008 Jun; 4(6):357-65. PubMed ID: 18469809 [TBL] [Abstract][Full Text] [Related]
7. Cdc7 as a potential new target for cancer therapy. Ito S; Taniyami C; Arai N; Masai H Drug News Perspect; 2008 Nov; 21(9):481-8. PubMed ID: 19180266 [TBL] [Abstract][Full Text] [Related]
8. Discovery and in vitro evaluation of potent kinase inhibitors: Pyrido[1',2':1,5]pyrazolo[3,4-d]pyrimidines. Alberti MJ; Auten EP; Lackey KE; McDonald OB; Wood ER; Preugschat F; Cutler GJ; Kane-Carson L; Liu W; Jung DK Bioorg Med Chem Lett; 2005 Aug; 15(16):3778-81. PubMed ID: 15993060 [TBL] [Abstract][Full Text] [Related]
9. N-substituted azaindoles as potent inhibitors of Cdc7 kinase. Bryan MC; Falsey JR; Frohn M; Reichelt A; Yao G; Bartberger MD; Bailis JM; Zalameda L; Miguel TS; Doherty EM; Allen JG Bioorg Med Chem Lett; 2013 Apr; 23(7):2056-60. PubMed ID: 23481650 [TBL] [Abstract][Full Text] [Related]
10. First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. Menichincheri M; Bargiotti A; Berthelsen J; Bertrand JA; Bossi R; Ciavolella A; Cirla A; Cristiani C; Croci V; D'Alessio R; Fasolini M; Fiorentini F; Forte B; Isacchi A; Martina K; Molinari A; Montagnoli A; Orsini P; Orzi F; Pesenti E; Pezzetta D; Pillan A; Poggesi I; Roletto F; Scolaro A; Tatò M; Tibolla M; Valsasina B; Varasi M; Volpi D; Santocanale C; Vanotti E J Med Chem; 2009 Jan; 52(2):293-307. PubMed ID: 19115845 [TBL] [Abstract][Full Text] [Related]
11. Single step synthesis of new fused pyrimidine derivatives and their evaluation as potent Aurora-A kinase inhibitors. Shaaban MR; Saleh TS; Mayhoub AS; Farag AM Eur J Med Chem; 2011 Sep; 46(9):3690-5. PubMed ID: 21664013 [TBL] [Abstract][Full Text] [Related]
12. The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: a new class of Aurora-A kinase inhibitors. Moriarty KJ; Koblish HK; Garrabrant T; Maisuria J; Khalil E; Ali F; Petrounia IP; Crysler CS; Maroney AC; Johnson DL; Galemmo RA Bioorg Med Chem Lett; 2006 Nov; 16(22):5778-83. PubMed ID: 16949284 [TBL] [Abstract][Full Text] [Related]
13. Identification of novel, potent and selective inhibitors of Polo-like kinase 1. Chen S; Bartkovitz D; Cai J; Chen Y; Chen Z; Chu XJ; Le K; Le NT; Luk KC; Mischke S; Naderi-Oboodi G; Boylan JF; Nevins T; Qing W; Chen Y; Wovkulich PM Bioorg Med Chem Lett; 2012 Jan; 22(2):1247-50. PubMed ID: 22172702 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Lin R; Johnson SG; Connolly PJ; Wetter SK; Binnun E; Hughes TV; Murray WV; Pandey NB; Moreno-Mazza SJ; Adams M; Fuentes-Pesquera AR; Middleton SA Bioorg Med Chem Lett; 2009 Apr; 19(8):2333-7. PubMed ID: 19286381 [TBL] [Abstract][Full Text] [Related]
15. Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors. Gopalsamy A; Ciszewski G; Hu Y; Lee F; Feldberg L; Frommer E; Kim S; Collins K; Wojciechowicz D; Mallon R Bioorg Med Chem Lett; 2009 May; 19(10):2735-8. PubMed ID: 19362830 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Reichelt A; Bailis JM; Bartberger MD; Yao G; Shu H; Kaller MR; Allen JG; Weidner MF; Keegan KS; Dao JH Eur J Med Chem; 2014 Jun; 80():364-82. PubMed ID: 24793884 [TBL] [Abstract][Full Text] [Related]
17. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases. McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056 [TBL] [Abstract][Full Text] [Related]
18. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach. Cheng AN; Lo YK; Lin YS; Tang TK; Hsu CH; Hsu JT; Lee AY EBioMedicine; 2018 Oct; 36():241-251. PubMed ID: 30293817 [TBL] [Abstract][Full Text] [Related]
19. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors. Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331 [TBL] [Abstract][Full Text] [Related]
20. Aminopyrimidinone cdc7 kinase inhibitors. Woods KW; Lai C; Miyashiro JM; Tong Y; Florjancic AS; Han EK; Soni N; Shi Y; Lasko L; Leverson JD; Johnson EF; Shoemaker AR; Penning TD Bioorg Med Chem Lett; 2012 Mar; 22(5):1940-3. PubMed ID: 22326396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]